Therefore, molecules targeting HSD17B13 Ser33 phosphorylation in a liver-specific manner may represent therapeutic agents in the treatment of NAFLD/NASH35. This evidence concerns the gene HSD17B13 and metabolic dysfunction-associated steatotic liver disease.